CriticalSecond-generation systemic triazole antifungal×Systemic antimycotics. Imidazole derivatives
Updated · Methodology
Mechanism
CYP3A4 and CYP3A5 metabolise isavuconazole (isavuconazole summary of product characteristics, SmPC, European Medicines Agency, EMA), and ketoconazole is a strong inhibitor of the enzyme CYP3A4 (ketoconazole SmPC, EMA). Ketoconazole 200 mg twice daily increased isavuconazole exposure (area under the curve, AUC) by 422% and its peak concentration by 9% (isavuconazole SmPC, EMA, and isavuconazole label, US Food and Drug Administration, FDA). The US label describes this as a more than 5-fold increase in exposure (FDA). CYP3A4 is also the main enzyme that metabolises ketoconazole (ketoconazole SmPC, EMA), and isavuconazole moderately inhibits this enzyme (EMA, FDA). The documents give no data on how isavuconazole changes ketoconazole levels.
Symptoms
Higher isavuconazole levels may bring more adverse reactions (isavuconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). At three times the usual maintenance dose, the following were more frequent: headache, dizziness, tingling, numbness in the mouth, sleepiness, poor attention, taste disturbance, dry mouth, diarrhoea, vomiting, flushing, anxiety, restlessness, palpitations, fast heart rate, sensitivity to light and joint pain (isavuconazole SmPC, EMA, and isavuconazole label, US Food and Drug Administration, FDA). Both drugs can damage the liver. Serious liver injury, including fatal cases and cases needing liver transplantation, has occurred with oral ketoconazole (ketoconazole label, FDA). Hepatitis, cholestasis and liver failure, including fatal cases, have been reported in seriously ill patients treated with azole antifungals, isavuconazole among them (isavuconazole label, FDA). Warning signs of liver injury with ketoconazole are loss of appetite, nausea, vomiting, fatigue, jaundice, abdominal pain and dark urine (ketoconazole SmPC, EMA). Ketoconazole can prolong the QT interval (FDA), while isavuconazole shortens it, more so at higher concentrations (EMA). The documents do not say how these effects combine.
Management
The combination is contraindicated: both the European and the US isavuconazole documents name ketoconazole among contraindicated drugs (isavuconazole summary of product characteristics, SmPC, European Medicines Agency, EMA, and isavuconazole label, US Food and Drug Administration, FDA). In the European Union, oral ketoconazole is authorised only for endogenous Cushing's syndrome (ketoconazole SmPC, EMA). In the US, it is authorised for systemic fungal infections when other therapies have failed or are not tolerated (ketoconazole label, FDA). If the treatment strategy for Cushing's syndrome changes, ketoconazole can be stopped at once, without tapering the dose (EMA). No document gives a waiting time between stopping ketoconazole and starting isavuconazole. The half-life of ketoconazole at doses above 400 mg/day is 3–10 hours (EMA), and the mean half-life of isavuconazole is 130 hours (FDA). The European ketoconazole SmPC recommends not combining it with drugs that can damage the liver, and the US label says such drugs should be avoided if possible (ketoconazole SmPC and label, EMA and FDA). With ketoconazole, measure liver enzymes and bilirubin before treatment, weekly during the first month and then monthly for 6 months (EMA). With isavuconazole, evaluate liver tests at the start and during treatment (isavuconazole label, FDA), and stop isavuconazole if signs of liver disease develop that may be due to it (FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Ketoconazole Tablets USP 200 mg prescribing information (2026)– FDA label, DailyMed setid 1d598696-c6f3-4b7c-ad73-949d2089df35, revised 08/2026, Contraindications
- EMA: Ficha técnica: Ketoconazol (EU/1/14/965), sección 4.3 (2025)– EMA, Ketoconazole Esteve 200 mg comprimidos (autorización europea por procedimiento centralizado), EU/1/14/965/001, ficha técnica (anexo I), información del producto actualizada el 05.05.2025, secciones 4.1, 4.2, 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Isavuconazol (EU/1/15/1036), sección 4.5 (2026)– EMA, Cresemba 100 mg cápsulas duras (Basilea Pharmaceutica Deutschland, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151036002, consultada 24.10.2026, sin fecha de revisión en CIMA, secciones 4.3, 4.4, 4.5, 4.9 y 5.2
- FDA: CRESEMBA (isavuconazonium sulfate) prescribing information (2025)– FDA, DailyMed setid 8f7f73b8-586a-4df0-935f-fecd4696c16c (Astellas Pharma US), revisión 04/2025 (versión 21), secciones 4, 5.1, 5.5, 7, 10 y 12.3
- EMA: Ficha técnica: Isavuconazol (EU/1/15/1036), sección 4.3 (2026)– EMA, Cresemba 100 mg cápsulas duras (Basilea Pharmaceutica Deutschland, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151036002, consultada 24.10.2026, sin fecha de revisión en CIMA, secciones 4.3, 4.4 y 4.5